These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 37204840)

  • 1. Nasopharyngeal carcinoma. A "different" head and neck tumour. Part B: treatment, prognostic factors, and outcomes.
    Cantù G
    Acta Otorhinolaryngol Ital; 2023 Jun; 43(3):155-169. PubMed ID: 37204840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
    Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature.
    Wang S; Li S; Shen L
    Curr Probl Cancer; 2018; 42(3):302-318. PubMed ID: 29759802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines.
    Simo R; Robinson M; Lei M; Sibtain A; Hickey S
    J Laryngol Otol; 2016 May; 130(S2):S97-S103. PubMed ID: 27841121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
    Kong F; Zhou J; Du C; He X; Kong L; Hu C; Ying H
    BMC Cancer; 2018 Nov; 18(1):1139. PubMed ID: 30453915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience.
    Jouin A; Helfre S; Bolle S; Claude L; Laprie A; Bogart E; Vigneron C; Potet H; Ducassou A; Claren A; Riet FG; Castex MP; Faure-Conter C; Fresneau B; Defachelles AS; Orbach D
    Strahlenther Onkol; 2019 Jun; 195(6):504-516. PubMed ID: 30963203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.
    Pan JJ; Ng WT; Zong JF; Chan LL; O'Sullivan B; Lin SJ; Sze HC; Chen YB; Choi HC; Guo QJ; Kan WK; Xiao YP; Wei X; Le QT; Glastonbury CM; Colevas AD; Weber RS; Shah JP; Lee AW
    Cancer; 2016 Feb; 122(4):546-58. PubMed ID: 26588425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasopharyngeal carcinoma. A "different" head and neck tumour. Part A: from histology to staging.
    Cantù G
    Acta Otorhinolaryngol Ital; 2023 Apr; 43(2):85-98. PubMed ID: 37099432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary tumor volume should be included in the TNM staging system of nasopharyngeal carcinoma.
    Liu D; Long G; Mei Q; Hu G
    Med Hypotheses; 2014 Apr; 82(4):486-7. PubMed ID: 24561054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity-modulated radiotherapy.
    Chang H; Peng L; Tao YL; Chen C; Xiao WW; Hu YH; Gao YH
    Cancer Med; 2019 Jun; 8(6):2823-2831. PubMed ID: 31006996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of residual or recurrent lymph nodes in the neck for patients with nasopharyngeal carcinoma after radiotherapy.
    Wang M; Xu Y; Chen X; Chen H; Gong H; Chen S
    J Cancer Res Ther; 2016; 12(2):909-14. PubMed ID: 27461673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of locally recurrent nasopharyngeal carcinoma.
    Lee AWM; Ng WT; Chan JYW; Corry J; Mäkitie A; Mendenhall WM; Rinaldo A; Rodrigo JP; Saba NF; Strojan P; Suárez C; Vermorken JB; Yom SS; Ferlito A
    Cancer Treat Rev; 2019 Sep; 79():101890. PubMed ID: 31470314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
    Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C
    Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of chemotherapy in stage IIb nasopharyngeal carcinoma.
    Pan XB; Zhu XD
    Chin J Cancer; 2012 Dec; 31(12):573-8. PubMed ID: 22776232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival.
    Fang FM; Huang TL; Lin YH; Chien CY; Chuang HC; Luo SD; Lin HC; Lin YT; Li SH; Liao KC; Tsai WL
    Head Neck; 2019 May; 41(5):1282-1289. PubMed ID: 30548091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
    Wang L; Wu Z; Xie D; Lv S; Xia L; Su Y
    Radiat Oncol; 2020 Jul; 15(1):160. PubMed ID: 32615984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and prognostic analyses of 110 patients with N3 nasopharyngeal carcinoma.
    Chen J; Liu T; Sun Q; Hu F
    Medicine (Baltimore); 2018 Dec; 97(49):e13483. PubMed ID: 30544441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of nasopharyngeal carcinoma patients with T1-2 stage in intensity-modulated radiotherapy era.
    Niu X; Xue F; Liu P; Hu C; He X
    Int J Med Sci; 2022; 19(2):267-273. PubMed ID: 35165512
    [No Abstract]   [Full Text] [Related]  

  • 20. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma.
    Ji X; Xie C; Hu D; Fan X; Zhou Y; Zheng Y
    PLoS One; 2013; 8(2):e56208. PubMed ID: 23441169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.